Group items tagged

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Specifically, this RFP focuses on: - developing novel PET ligands for clinical use - supporting novel CSF biomarkers - validating established MRI approaches in larger cohorts Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: - Neuronal loss - Vascular injury and blood-brain barrier integrity - Mitochondria and metabolic function - Protein misfolding/proteostasis - Oxidative stress - White matter changes - Other novel targets supported by compelling biological rationale and connection to disease The ADDF has limited interest in CSF measures of amyloid and tau.

LEO Foundation 'Open competition grants' are given to support the best dermatology research projects worldwide. Thus, we welcome applications from research projects that: - Improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms - Address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved

The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).

This FOA encourages innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease (AD).

This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.

This FOA seeks applications that propose innovative research strategies aimed at increasing the understanding of the changes in cellular architecture that occur during the aging process. Studies on cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and signaling or regulatory molecules controlling cellular architecture will be considered. There is interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications, and in spatio-temporal relationships during the aging process and in age-related diseases.

This FOA seeks applications that propose innovative research strategies aimed at increasing the understanding of the changes in cellular architecture that occur during the aging process. Studies on cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and signaling or regulatory molecules controlling cellular architecture will be considered. There is interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications, and in spatio-temporal relationships during the aging process and in age-related diseases.

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.  

The specific objective of the "E-Rare-3" call is to promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or have achieved a significant stage in the development process in rare indications. Projects should aim at discovering new therapeutic uses for agents whose clinical safety has already been characterized to move quickly into proof of concept trials in the selected rare diseases' patient population.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

Chemical modifications of protein, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests RNA modifications have substantive roles in multiple basic biological processes. Epitranscriptomics can be defined as the aggregate suite of functional biochemical modifications to the transcriptome within a cell. Recent studies in yeast, Drosophila, rodent and human models demonstrate that stressors can induce RNA modifications, with specific reprogramming of some regulatory RNAs. The NIEHS seeks to solicit innovative, mechanistic research applications that are focused on how environmental exposures are associated and involved with the functional activities of RNA modifications and pathways that may be modified or misregulated, associated with adverse health outcomes and/or be useful as biomarkers of exposure and/or exposure-induced pathologies. The study of functional chemical RNA modification has identified important emerging roles in cellular regulation and gene expression. However, the impact of environmental exposures on functional RNA modifications has been relatively understudied and may present a new mechanism for enhanced understanding the relationships between exposures and the development of complex human diseases. The NIEHS will use the R01 mechanism to support hypothesis driven research using approaches that incorporate principles of toxicology with RNA modification biological and/or chemical expertise and utilizes state of the art technologies.

This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure.

The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

To establish a rare disease consortium focusing on clinical outcome assessments appropriate for use in drug development to demonstrate clinical benefit.    

The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease. 

Supported by the American Heart Association Strategically Focused Research Networks, there is a two-year postdoctoral fellowship opportunity listed by institution for the funded research networks. Fellows with a strong interest in either prevention, hypertension, disparities, women's health, or heart failure-related to cardiovascular disease and/or stroke research, commitment to multi-disciplinary team science approach at the population, clinical and basic science levels and excellent communication skills. The center fellow will be highly involved in the projects being proposed by their institution, will be encouraged to collaborate with fellows across the network, and work closely with their Center Director and Training Director on their Center's individualized multidisciplinary training plan. Please refer to the SFRN Awardees webpage for a detailed list of each institution's projects within the networks

This Administrative Supplement funding opportunity is part of the Common Fund Metabolomics Program created to increase and improve the nation's ability to undertake metabolomics analyses in translational and clinical research. Metabolomics has great potential to advance our understanding of human diseases, but requires specialized expertise in metabolomics study design, technology, and data analysis and interpretation.